| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 69 | 2024 | 1537 | 11.440 |
Why?
|
| Epoprostenol | 16 | 2024 | 254 | 5.740 |
Why?
|
| Lung Diseases, Interstitial | 10 | 2024 | 808 | 3.710 |
Why?
|
| Exercise Tolerance | 22 | 2023 | 770 | 3.580 |
Why?
|
| Pulmonary Artery | 28 | 2022 | 1912 | 3.550 |
Why?
|
| Vascular Resistance | 20 | 2023 | 936 | 2.580 |
Why?
|
| Antihypertensive Agents | 18 | 2024 | 2046 | 2.530 |
Why?
|
| Hyperoxia | 10 | 2010 | 262 | 2.070 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 5 | 2020 | 101 | 2.000 |
Why?
|
| Ventricular Function, Right | 7 | 2021 | 591 | 1.640 |
Why?
|
| Exercise Test | 23 | 2023 | 2074 | 1.580 |
Why?
|
| Ventricular Dysfunction, Right | 7 | 2021 | 581 | 1.440 |
Why?
|
| Pulmonary Wedge Pressure | 12 | 2024 | 264 | 1.400 |
Why?
|
| Stroke Volume | 15 | 2021 | 5007 | 1.380 |
Why?
|
| Hemodynamics | 15 | 2024 | 4199 | 1.310 |
Why?
|
| Pulmonary Circulation | 9 | 2022 | 739 | 1.280 |
Why?
|
| Prostaglandins I | 2 | 2020 | 13 | 1.220 |
Why?
|
| Dyspnea | 7 | 2021 | 1303 | 1.090 |
Why?
|
| Ventricular Pressure | 4 | 2021 | 199 | 1.060 |
Why?
|
| Interleukin-6 | 10 | 2009 | 3200 | 1.020 |
Why?
|
| Heart Failure | 12 | 2021 | 10900 | 0.960 |
Why?
|
| Interleukin-11 | 6 | 2008 | 63 | 0.960 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2016 | 153 | 0.890 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2022 | 61 | 0.820 |
Why?
|
| Tricuspid Valve | 4 | 2019 | 403 | 0.800 |
Why?
|
| Exercise | 19 | 2023 | 5615 | 0.740 |
Why?
|
| Heart Ventricles | 10 | 2021 | 3821 | 0.720 |
Why?
|
| Infusion Pumps, Implantable | 2 | 2017 | 156 | 0.700 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2019 | 349 | 0.660 |
Why?
|
| Gelsolin | 3 | 2008 | 190 | 0.650 |
Why?
|
| Acute Lung Injury | 4 | 2010 | 380 | 0.640 |
Why?
|
| Cytoprotection | 2 | 2009 | 210 | 0.630 |
Why?
|
| Administration, Inhalation | 4 | 2023 | 1105 | 0.630 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2021 | 478 | 0.620 |
Why?
|
| Lung | 17 | 2022 | 9856 | 0.600 |
Why?
|
| Lung Diseases | 5 | 2017 | 1886 | 0.580 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 451 | 0.570 |
Why?
|
| Pulmonary Alveoli | 2 | 2010 | 675 | 0.550 |
Why?
|
| Pulmonary Medicine | 1 | 2018 | 213 | 0.550 |
Why?
|
| Oxygen | 12 | 2022 | 4189 | 0.490 |
Why?
|
| Oxygen Consumption | 7 | 2021 | 1869 | 0.450 |
Why?
|
| Endpoint Determination | 1 | 2015 | 601 | 0.430 |
Why?
|
| Humans | 134 | 2024 | 744343 | 0.430 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 514 | 0.420 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2017 | 496 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 933 | 0.400 |
Why?
|
| Respiratory Function Tests | 4 | 2021 | 1616 | 0.400 |
Why?
|
| Anticoagulants | 2 | 2017 | 4599 | 0.390 |
Why?
|
| Fatigue Syndrome, Chronic | 2 | 2023 | 214 | 0.380 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 3670 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 941 | 0.360 |
Why?
|
| Respiratory Mucosa | 3 | 2010 | 427 | 0.340 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2008 | 22 | 0.330 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2009 | 75 | 0.330 |
Why?
|
| Sulfones | 1 | 2011 | 437 | 0.330 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2008 | 110 | 0.320 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 996 | 0.320 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2009 | 295 | 0.320 |
Why?
|
| DNA Fragmentation | 2 | 1999 | 242 | 0.320 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 590 | 0.310 |
Why?
|
| Female | 79 | 2023 | 380194 | 0.310 |
Why?
|
| Aged | 53 | 2023 | 163280 | 0.310 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2008 | 175 | 0.310 |
Why?
|
| Hydrogen Peroxide | 3 | 2009 | 731 | 0.300 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2023 | 3772 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2009 | 1434 | 0.300 |
Why?
|
| Male | 78 | 2023 | 350118 | 0.300 |
Why?
|
| Treatment Outcome | 17 | 2024 | 63114 | 0.290 |
Why?
|
| Middle Aged | 62 | 2022 | 213383 | 0.290 |
Why?
|
| Disease Progression | 3 | 2022 | 13284 | 0.290 |
Why?
|
| Cardiology | 1 | 2018 | 1668 | 0.290 |
Why?
|
| Pulmonary Gas Exchange | 6 | 2020 | 382 | 0.280 |
Why?
|
| Double-Blind Method | 8 | 2023 | 12026 | 0.280 |
Why?
|
| Calcium Channel Blockers | 2 | 2007 | 690 | 0.280 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 215 | 0.270 |
Why?
|
| Prostaglandins | 1 | 2007 | 405 | 0.270 |
Why?
|
| MicroRNAs | 6 | 2022 | 3752 | 0.270 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2016 | 2073 | 0.260 |
Why?
|
| Caspase 3 | 1 | 2008 | 758 | 0.260 |
Why?
|
| Echocardiography, Doppler | 3 | 2017 | 935 | 0.260 |
Why?
|
| GTP Phosphohydrolases | 1 | 2009 | 509 | 0.260 |
Why?
|
| Isoxazoles | 1 | 2007 | 216 | 0.260 |
Why?
|
| Pulmonary Embolism | 3 | 2022 | 2376 | 0.260 |
Why?
|
| Protein C | 1 | 2005 | 138 | 0.260 |
Why?
|
| Piperazines | 2 | 2014 | 2488 | 0.250 |
Why?
|
| Myocardium | 3 | 2017 | 4776 | 0.240 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2008 | 306 | 0.240 |
Why?
|
| Mice, Transgenic | 13 | 2012 | 9734 | 0.240 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2003 | 29 | 0.230 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2014 | 1504 | 0.230 |
Why?
|
| Least-Squares Analysis | 2 | 2021 | 379 | 0.230 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2019 | 2916 | 0.220 |
Why?
|
| Membrane Transport Proteins | 1 | 2009 | 1028 | 0.220 |
Why?
|
| Adult | 51 | 2024 | 214055 | 0.210 |
Why?
|
| Shock, Septic | 2 | 2007 | 775 | 0.210 |
Why?
|
| Thiophenes | 1 | 2007 | 588 | 0.210 |
Why?
|
| Organizational Affiliation | 1 | 2001 | 33 | 0.210 |
Why?
|
| Systole | 3 | 2021 | 958 | 0.210 |
Why?
|
| Echocardiography | 8 | 2021 | 5102 | 0.210 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2021 | 56 | 0.200 |
Why?
|
| Radionuclide Imaging | 13 | 2003 | 2031 | 0.200 |
Why?
|
| Actins | 2 | 2008 | 2121 | 0.200 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 2274 | 0.200 |
Why?
|
| Perfusion Imaging | 2 | 2022 | 195 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 7913 | 0.200 |
Why?
|
| Anaerobic Threshold | 2 | 2019 | 52 | 0.200 |
Why?
|
| Endothelial Cells | 8 | 2018 | 3479 | 0.200 |
Why?
|
| Medication Adherence | 1 | 2012 | 2063 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1889 | 0.190 |
Why?
|
| Schistosomiasis | 1 | 2021 | 62 | 0.190 |
Why?
|
| Connecticut | 1 | 2021 | 366 | 0.190 |
Why?
|
| Endothelium | 1 | 2003 | 778 | 0.180 |
Why?
|
| Pulmonary Ventilation | 2 | 2019 | 373 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2503 | 0.180 |
Why?
|
| Retrospective Studies | 13 | 2024 | 77449 | 0.180 |
Why?
|
| Public Sector | 1 | 2001 | 265 | 0.180 |
Why?
|
| Vasodilator Agents | 4 | 2020 | 977 | 0.180 |
Why?
|
| Cells, Cultured | 12 | 2019 | 19229 | 0.170 |
Why?
|
| Aldosterone | 2 | 2016 | 877 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 2938 | 0.170 |
Why?
|
| Iron-Sulfur Proteins | 2 | 2019 | 82 | 0.170 |
Why?
|
| Respiratory Insufficiency | 2 | 2008 | 1199 | 0.170 |
Why?
|
| Vital Capacity | 1 | 2021 | 925 | 0.160 |
Why?
|
| Private Sector | 1 | 2001 | 392 | 0.160 |
Why?
|
| Survival Rate | 8 | 2021 | 12788 | 0.160 |
Why?
|
| Oxidants | 2 | 2009 | 164 | 0.160 |
Why?
|
| Utah | 1 | 2018 | 126 | 0.160 |
Why?
|
| Collagen Type III | 1 | 2018 | 90 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 2 | 2021 | 2007 | 0.160 |
Why?
|
| Extracellular Matrix | 2 | 2016 | 1741 | 0.160 |
Why?
|
| Sepsis | 2 | 2010 | 2593 | 0.160 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 264 | 0.160 |
Why?
|
| Atrial Function | 1 | 2018 | 107 | 0.160 |
Why?
|
| Up-Regulation | 4 | 2021 | 4217 | 0.160 |
Why?
|
| Cell Death | 3 | 2005 | 1706 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 972 | 0.150 |
Why?
|
| Blood Pressure | 5 | 2017 | 8554 | 0.150 |
Why?
|
| Animals | 30 | 2021 | 168757 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 39050 | 0.150 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3086 | 0.150 |
Why?
|
| Mice | 22 | 2021 | 81183 | 0.150 |
Why?
|
| Prognosis | 7 | 2021 | 29063 | 0.150 |
Why?
|
| Time Factors | 11 | 2017 | 40075 | 0.150 |
Why?
|
| Injections, Intra-Arterial | 1 | 2017 | 193 | 0.150 |
Why?
|
| Verapamil | 1 | 1997 | 244 | 0.150 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2009 | 452 | 0.140 |
Why?
|
| Gastric Emptying | 1 | 1999 | 233 | 0.140 |
Why?
|
| Quality of Life | 4 | 2023 | 12804 | 0.140 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2017 | 86 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2022 | 2266 | 0.140 |
Why?
|
| Pyridines | 1 | 2008 | 2825 | 0.140 |
Why?
|
| Ventricular Function | 2 | 2018 | 416 | 0.140 |
Why?
|
| Microvessels | 1 | 2021 | 544 | 0.140 |
Why?
|
| Mitochondria | 2 | 2009 | 3520 | 0.140 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 131 | 0.140 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1161 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 21827 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 314 | 0.140 |
Why?
|
| DNA Damage | 1 | 2006 | 2432 | 0.140 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 57776 | 0.140 |
Why?
|
| Aortography | 1 | 2017 | 437 | 0.140 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 367 | 0.140 |
Why?
|
| Cardiac Output | 3 | 2015 | 854 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2024 | 2309 | 0.130 |
Why?
|
| Propranolol | 1 | 1997 | 502 | 0.130 |
Why?
|
| Glycine | 1 | 2019 | 671 | 0.130 |
Why?
|
| World Health Organization | 1 | 2001 | 1318 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 9959 | 0.130 |
Why?
|
| Sex Distribution | 1 | 2021 | 2297 | 0.130 |
Why?
|
| Drug Industry | 1 | 2001 | 746 | 0.130 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1997 | 249 | 0.130 |
Why?
|
| Lipid Peroxidation | 3 | 2009 | 270 | 0.130 |
Why?
|
| Cooperative Behavior | 2 | 2018 | 1504 | 0.120 |
Why?
|
| Sulfur | 1 | 2015 | 166 | 0.120 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2017 | 272 | 0.120 |
Why?
|
| Posture | 2 | 2017 | 958 | 0.120 |
Why?
|
| Cell Proliferation | 6 | 2022 | 10481 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2024 | 10252 | 0.120 |
Why?
|
| Thallium Radioisotopes | 5 | 1993 | 139 | 0.120 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 950 | 0.120 |
Why?
|
| Heart | 6 | 2023 | 4467 | 0.120 |
Why?
|
| Protein Transport | 2 | 2010 | 1988 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2016 | 541 | 0.120 |
Why?
|
| Apoptosis | 6 | 2016 | 9727 | 0.110 |
Why?
|
| Phenylpropionates | 1 | 2013 | 30 | 0.110 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2013 | 30 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1997 | 657 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2022 | 687 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2001 | 880 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 479 | 0.110 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 1585 | 0.110 |
Why?
|
| Community Pharmacy Services | 1 | 2012 | 46 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 3047 | 0.110 |
Why?
|
| Carbolines | 1 | 2014 | 265 | 0.110 |
Why?
|
| Cytomegalovirus | 1 | 1997 | 732 | 0.100 |
Why?
|
| Phosphoproteins | 2 | 2018 | 2440 | 0.100 |
Why?
|
| Cardiac Output, Low | 1 | 2012 | 195 | 0.100 |
Why?
|
| Vasoconstriction | 1 | 2014 | 597 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 3537 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7880 | 0.100 |
Why?
|
| Purines | 2 | 2014 | 594 | 0.100 |
Why?
|
| Heart Conduction System | 1 | 1997 | 1047 | 0.100 |
Why?
|
| Rats | 9 | 2021 | 24260 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2021 | 8301 | 0.100 |
Why?
|
| Pyridazines | 1 | 2013 | 202 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2014 | 281 | 0.100 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 13989 | 0.100 |
Why?
|
| Fibrosis | 1 | 2018 | 2029 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 23338 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 1938 | 0.100 |
Why?
|
| Signal Transduction | 8 | 2019 | 23403 | 0.100 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2015 | 500 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2008 | 643 | 0.100 |
Why?
|
| Medication Therapy Management | 1 | 2012 | 127 | 0.100 |
Why?
|
| Dietary Fats | 1 | 1999 | 2017 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 1184 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 2649 | 0.090 |
Why?
|
| Patient Positioning | 3 | 2020 | 324 | 0.090 |
Why?
|
| Injections, Subcutaneous | 2 | 2023 | 666 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2015 | 5317 | 0.090 |
Why?
|
| Respiration Disorders | 1 | 2013 | 371 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 1997 | 820 | 0.090 |
Why?
|
| Lung Injury | 2 | 2005 | 436 | 0.090 |
Why?
|
| Diuretics | 1 | 2013 | 592 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 10943 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1671 | 0.090 |
Why?
|
| Spironolactone | 1 | 2013 | 382 | 0.090 |
Why?
|
| Aorta | 1 | 2017 | 2061 | 0.090 |
Why?
|
| Nitric Oxide | 2 | 2022 | 2132 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 19905 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 1119 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2015 | 3913 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2018 | 2488 | 0.090 |
Why?
|
| Hyperaldosteronism | 1 | 2012 | 240 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2013 | 345 | 0.090 |
Why?
|
| ROC Curve | 4 | 2018 | 3527 | 0.090 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2008 | 5 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2000 | 768 | 0.080 |
Why?
|
| Phosphoserine | 1 | 2009 | 206 | 0.080 |
Why?
|
| Emergency Treatment | 1 | 2013 | 517 | 0.080 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2008 | 59 | 0.080 |
Why?
|
| Uteroglobin | 1 | 2008 | 58 | 0.080 |
Why?
|
| Blood Cells | 1 | 2010 | 309 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 817 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2015 | 1301 | 0.080 |
Why?
|
| Massachusetts | 1 | 2021 | 8663 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2017 | 1654 | 0.080 |
Why?
|
| APACHE | 1 | 2008 | 277 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2008 | 195 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2018 | 5985 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 720 | 0.080 |
Why?
|
| Pilot Projects | 5 | 2018 | 8324 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2009 | 175 | 0.080 |
Why?
|
| Arterioles | 1 | 2008 | 254 | 0.080 |
Why?
|
| Placenta | 1 | 2017 | 1698 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 215 | 0.080 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2009 | 154 | 0.080 |
Why?
|
| Macrophages, Alveolar | 1 | 2010 | 407 | 0.080 |
Why?
|
| PPAR gamma | 3 | 2015 | 493 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 12072 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 264 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2017 | 2925 | 0.070 |
Why?
|
| Asthma | 1 | 2006 | 6011 | 0.070 |
Why?
|
| Gene Regulatory Networks | 2 | 2014 | 1708 | 0.070 |
Why?
|
| Swine | 1 | 2017 | 5917 | 0.070 |
Why?
|
| Sex Factors | 2 | 2021 | 10397 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2018 | 2531 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 4456 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 2109 | 0.070 |
Why?
|
| United States | 6 | 2021 | 69872 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 1082 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2008 | 315 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2008 | 1086 | 0.070 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2017 | 1632 | 0.070 |
Why?
|
| Citrates | 2 | 2005 | 131 | 0.070 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1547 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2010 | 1341 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 2915 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 697 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2012 | 1462 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 3870 | 0.070 |
Why?
|
| Potassium | 1 | 2010 | 1336 | 0.070 |
Why?
|
| Gallium | 1 | 2005 | 28 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2005 | 76 | 0.070 |
Why?
|
| Endotoxemia | 1 | 2007 | 207 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2019 | 3505 | 0.070 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 15540 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2008 | 1185 | 0.070 |
Why?
|
| Dioxoles | 1 | 2005 | 104 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 873 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3528 | 0.060 |
Why?
|
| Boston | 1 | 2018 | 9313 | 0.060 |
Why?
|
| Prospective Studies | 7 | 2021 | 53288 | 0.060 |
Why?
|
| Intensive Care Units | 3 | 2013 | 3679 | 0.060 |
Why?
|
| Protein Interaction Mapping | 1 | 2009 | 627 | 0.060 |
Why?
|
| Thallium | 6 | 1987 | 101 | 0.060 |
Why?
|
| Pregnancy | 2 | 2017 | 29144 | 0.060 |
Why?
|
| Antioxidants | 3 | 2003 | 1663 | 0.060 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 972 | 0.060 |
Why?
|
| Aortitis | 1 | 2005 | 74 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 1738 | 0.060 |
Why?
|
| Organ Specificity | 1 | 2009 | 2008 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2005 | 1107 | 0.060 |
Why?
|
| Protein Multimerization | 1 | 2009 | 970 | 0.060 |
Why?
|
| Radioisotopes | 7 | 1987 | 499 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2005 | 367 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2008 | 1850 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 1285 | 0.060 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 2025 | 0.060 |
Why?
|
| DEAE-Dextran | 1 | 2023 | 10 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2005 | 424 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 1157 | 0.060 |
Why?
|
| Legionnaires' Disease | 1 | 2003 | 48 | 0.060 |
Why?
|
| Protein Isoforms | 2 | 2006 | 1730 | 0.060 |
Why?
|
| Respiratory System Agents | 1 | 2023 | 29 | 0.060 |
Why?
|
| Thrombolytic Therapy | 2 | 2022 | 2161 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 987 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6234 | 0.060 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2006 | 367 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 7279 | 0.060 |
Why?
|
| Systems Biology | 2 | 2018 | 469 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2009 | 3701 | 0.050 |
Why?
|
| Pyridostigmine Bromide | 1 | 2022 | 31 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 2400 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2009 | 1538 | 0.050 |
Why?
|
| Incidence | 1 | 2021 | 20947 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2008 | 2726 | 0.050 |
Why?
|
| Stress, Physiological | 2 | 2009 | 1403 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 1990 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 18029 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2008 | 3508 | 0.050 |
Why?
|
| Models, Biological | 2 | 2015 | 9583 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 15076 | 0.050 |
Why?
|
| Acute Disease | 3 | 2022 | 7149 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2003 | 337 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 6489 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 627 | 0.050 |
Why?
|
| Rest | 2 | 2016 | 901 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3507 | 0.050 |
Why?
|
| Pneumonia | 2 | 2003 | 2133 | 0.050 |
Why?
|
| Decision Making | 1 | 2015 | 3887 | 0.050 |
Why?
|
| Epithelium | 1 | 2006 | 1679 | 0.050 |
Why?
|
| Physical Exertion | 3 | 2014 | 695 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 40561 | 0.050 |
Why?
|
| Resuscitation | 1 | 2005 | 658 | 0.050 |
Why?
|
| Endocarditis | 1 | 2005 | 350 | 0.050 |
Why?
|
| Young Adult | 6 | 2019 | 56430 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 648 | 0.050 |
Why?
|
| Trans-Activators | 2 | 2016 | 2924 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2012 | 9849 | 0.040 |
Why?
|
| Cattle | 1 | 2006 | 3922 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16365 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1783 | 0.040 |
Why?
|
| Adolescent | 9 | 2021 | 85781 | 0.040 |
Why?
|
| Computational Biology | 1 | 2012 | 3521 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8089 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2021 | 1573 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 531 | 0.040 |
Why?
|
| Prosthesis-Related Infections | 1 | 2005 | 538 | 0.040 |
Why?
|
| DNA Replication | 1 | 2006 | 1399 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2001 | 429 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2016 | 12208 | 0.040 |
Why?
|
| Elasticity | 1 | 2021 | 657 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12959 | 0.040 |
Why?
|
| Spirometry | 1 | 2001 | 864 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2019 | 201 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 1997 | 3240 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2000 | 389 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2008 | 3690 | 0.040 |
Why?
|
| Sarcoma | 2 | 2005 | 1897 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20129 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 4554 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2018 | 180 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 694 | 0.040 |
Why?
|
| Catheterization | 1 | 2003 | 1470 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2009 | 8436 | 0.040 |
Why?
|
| Logistic Models | 1 | 2012 | 13408 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2008 | 3023 | 0.040 |
Why?
|
| Stem Cells | 1 | 2010 | 3567 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 2569 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 949 | 0.040 |
Why?
|
| Coronary Disease | 7 | 1988 | 6077 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2021 | 21746 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3610 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 850 | 0.030 |
Why?
|
| Radiography | 2 | 2008 | 7023 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1997 | 258 | 0.030 |
Why?
|
| Consensus | 1 | 2005 | 2959 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 1488 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 104 | 0.030 |
Why?
|
| Respiratory Mechanics | 1 | 2020 | 686 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 72290 | 0.030 |
Why?
|
| Heart Block | 1 | 1997 | 410 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 1363 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 12745 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6622 | 0.030 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 115 | 0.030 |
Why?
|
| Pulmonary Veins | 1 | 2021 | 761 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2005 | 1922 | 0.030 |
Why?
|
| Supine Position | 1 | 2015 | 205 | 0.030 |
Why?
|
| Endothelins | 1 | 2014 | 138 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2003 | 1153 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2000 | 879 | 0.030 |
Why?
|
| Prevalence | 1 | 2011 | 15226 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1998 | 1263 | 0.030 |
Why?
|
| Bicycling | 1 | 2015 | 176 | 0.030 |
Why?
|
| Systems Theory | 1 | 2014 | 60 | 0.030 |
Why?
|
| Diastole | 1 | 2016 | 791 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2008 | 9146 | 0.030 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2019 | 591 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 2187 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 223 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2018 | 1572 | 0.030 |
Why?
|
| Collagen | 2 | 2016 | 2689 | 0.030 |
Why?
|
| Endothelin-1 | 1 | 2014 | 314 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1179 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 252 | 0.030 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1993 | 109 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 5535 | 0.030 |
Why?
|
| Kenya | 1 | 2015 | 685 | 0.030 |
Why?
|
| Bronchi | 1 | 1997 | 840 | 0.030 |
Why?
|
| Blood Circulation | 1 | 2013 | 251 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2021 | 14557 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1998 | 1609 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 599 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15165 | 0.030 |
Why?
|
| Pacemaker, Artificial | 1 | 1997 | 816 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2014 | 572 | 0.020 |
Why?
|
| Biopsy | 1 | 2003 | 6756 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 1991 | 114 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2015 | 2557 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2022 | 3461 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2009 | 68 | 0.020 |
Why?
|
| Pressure | 1 | 2013 | 1203 | 0.020 |
Why?
|
| Chest Pain | 1 | 1997 | 1114 | 0.020 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1990 | 136 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 1438 | 0.020 |
Why?
|
| Heart Rate | 2 | 2019 | 4091 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2010 | 403 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2016 | 956 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1990 | 178 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1993 | 2529 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 987 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2008 | 44 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1240 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5078 | 0.020 |
Why?
|
| Cell Line | 1 | 2003 | 15997 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2013 | 1743 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5097 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1114 | 0.020 |
Why?
|
| Shock | 1 | 2010 | 318 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 25625 | 0.020 |
Why?
|
| Ventilator Weaning | 1 | 2008 | 148 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1993 | 881 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1997 | 1470 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1991 | 1032 | 0.020 |
Why?
|
| Total Quality Management | 1 | 2008 | 274 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 7181 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
| Respiration | 1 | 2013 | 1653 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 1676 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 2418 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2015 | 1491 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 4420 | 0.020 |
Why?
|
| Infant | 2 | 2019 | 35136 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 9386 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 5882 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 14722 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 964 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 9648 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 1991 | 783 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4204 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2008 | 352 | 0.020 |
Why?
|
| Ganglia, Spinal | 1 | 1988 | 519 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2005 | 5179 | 0.020 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2005 | 91 | 0.020 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1985 | 116 | 0.020 |
Why?
|
| Dendrites | 1 | 1988 | 485 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 1988 | 1144 | 0.020 |
Why?
|
| Peritonitis | 1 | 2007 | 365 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2005 | 287 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6895 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1997 | 2987 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 642 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2006 | 370 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 1475 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 1866 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 565 | 0.010 |
Why?
|
| Perfusion | 1 | 2008 | 1360 | 0.010 |
Why?
|
| Culture Media | 1 | 2005 | 908 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 7659 | 0.010 |
Why?
|
| Tretinoin | 1 | 2005 | 517 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2005 | 592 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 928 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 3396 | 0.010 |
Why?
|
| Education, Medical | 1 | 2013 | 1721 | 0.010 |
Why?
|
| Heart Aneurysm | 1 | 1981 | 120 | 0.010 |
Why?
|
| Technetium | 1 | 1981 | 334 | 0.010 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2000 | 31 | 0.010 |
Why?
|
| Movement | 1 | 1988 | 1471 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6365 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6196 | 0.010 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2000 | 61 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 1364 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 1981 | 330 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2009 | 6459 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 149 | 0.010 |
Why?
|
| Child | 2 | 2019 | 77709 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 2216 | 0.010 |
Why?
|
| Walking | 1 | 2006 | 1180 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1983 | 793 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 772 | 0.010 |
Why?
|
| Hospitalization | 1 | 2018 | 10262 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 784 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2013 | 3309 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 1991 | 2282 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 597 | 0.010 |
Why?
|
| Length of Stay | 1 | 2010 | 6309 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4933 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 2645 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 41006 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 934 | 0.010 |
Why?
|
| Critical Illness | 1 | 2008 | 2670 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 2749 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 2645 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 4161 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2007 | 4217 | 0.010 |
Why?
|
| Mutation | 1 | 2019 | 29786 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 2785 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 13881 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 6364 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 8949 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2008 | 4931 | 0.010 |
Why?
|
| Antibodies | 1 | 2000 | 2460 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 7322 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2000 | 11366 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13033 | 0.010 |
Why?
|
| Citric Acid | 1 | 1990 | 126 | 0.010 |
Why?
|
| Supination | 1 | 1989 | 68 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1979 | 2289 | 0.010 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1967 | 25 | 0.000 |
Why?
|
| Globulins | 1 | 1967 | 19 | 0.000 |
Why?
|
| Porphyrias | 1 | 1967 | 57 | 0.000 |
Why?
|
| False Positive Reactions | 1 | 1989 | 981 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1967 | 286 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1990 | 13695 | 0.000 |
Why?
|
| Macrophages | 1 | 2000 | 5655 | 0.000 |
Why?
|
| Krypton | 1 | 1985 | 21 | 0.000 |
Why?
|
| Dilatation, Pathologic | 1 | 1987 | 520 | 0.000 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1985 | 67 | 0.000 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1993 | 3479 | 0.000 |
Why?
|
| Coronary Angiography | 2 | 1987 | 4577 | 0.000 |
Why?
|
| Kymography | 1 | 1981 | 14 | 0.000 |
Why?
|
| Cell Division | 1 | 1988 | 4568 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1981 | 588 | 0.000 |
Why?
|
| Axons | 1 | 1988 | 1684 | 0.000 |
Why?
|
| Constriction, Pathologic | 1 | 1983 | 1107 | 0.000 |
Why?
|
| Electrocardiography | 2 | 1983 | 6442 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1981 | 1681 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1979 | 15295 | 0.000 |
Why?
|
| Fluoroscopy | 1 | 1981 | 924 | 0.000 |
Why?
|
| Myocardial Infarction | 3 | 1981 | 11727 | 0.000 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1987 | 3327 | 0.000 |
Why?
|
| Hypothermia, Induced | 1 | 1979 | 752 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1993 | 11524 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1981 | 5391 | 0.000 |
Why?
|